437 related articles for article (PubMed ID: 25844549)
1. Simultaneous carcinomas of the breast and ovary: utility of Pax-8, WT-1, and GATA3 for distinguishing independent primary tumors from metastases.
Espinosa I; Gallardo A; D'Angelo E; Mozos A; Lerma E; Prat J
Int J Gynecol Pathol; 2015 May; 34(3):257-65. PubMed ID: 25844549
[TBL] [Abstract][Full Text] [Related]
2. Expression of pax8 as a useful marker in distinguishing ovarian carcinomas from mammary carcinomas.
Nonaka D; Chiriboga L; Soslow RA
Am J Surg Pathol; 2008 Oct; 32(10):1566-71. PubMed ID: 18724243
[TBL] [Abstract][Full Text] [Related]
3. Expression of WT1, CA 125, and GCDFP-15 as useful markers in the differential diagnosis of primary ovarian carcinomas versus metastatic breast cancer to the ovary.
Tornos C; Soslow R; Chen S; Akram M; Hummer AJ; Abu-Rustum N; Norton L; Tan LK
Am J Surg Pathol; 2005 Nov; 29(11):1482-9. PubMed ID: 16224215
[TBL] [Abstract][Full Text] [Related]
4. Significantly increased PELP1 protein expression in primary and metastatic triple-negative breast carcinoma: comparison with GATA3 expression and PELP1's potential role in triple-negative breast carcinoma.
Dang DN; Raj G; Sarode V; Molberg KH; Vadlamudi RK; Peng Y
Hum Pathol; 2015 Dec; 46(12):1829-35. PubMed ID: 26428280
[TBL] [Abstract][Full Text] [Related]
5. PAX 2: a novel Müllerian marker for serous papillary carcinomas to differentiate from micropapillary breast carcinoma.
Chivukula M; Dabbs DJ; O'Connor S; Bhargava R
Int J Gynecol Pathol; 2009 Nov; 28(6):570-8. PubMed ID: 19851209
[TBL] [Abstract][Full Text] [Related]
6. Is GATA3 expression maintained in regional metastases?: a study of paired primary and metastatic urothelial carcinomas.
Zhao L; Antic T; Witten D; Paner GP; Taxy JB; Husain A; Gwin K; Mirza MK; Lingen MW; Tretiakova MS
Am J Surg Pathol; 2013 Dec; 37(12):1876-81. PubMed ID: 24121175
[TBL] [Abstract][Full Text] [Related]
7. Strong androgen receptor expression can aid in distinguishing GATA3+ metastases.
Boto A; Harigopal M
Hum Pathol; 2018 May; 75():63-70. PubMed ID: 29408697
[TBL] [Abstract][Full Text] [Related]
8. Utility of paired box gene 8 (PAX8) expression in fluid and fine-needle aspiration cytology: an immunohistochemical study of metastatic ovarian serous carcinoma.
McKnight R; Cohen C; Siddiqui MT
Cancer Cytopathol; 2010 Oct; 118(5):298-302. PubMed ID: 20572292
[TBL] [Abstract][Full Text] [Related]
9. PAX8 discriminates ovarian metastases from adnexal tumors and other cutaneous metastases.
Fujiwara M; Taube J; Sharma M; McCalmont TH; Kim J
J Cutan Pathol; 2010 Sep; 37(9):938-43. PubMed ID: 20492080
[TBL] [Abstract][Full Text] [Related]
10. GATA3: a promising marker for metastatic breast carcinoma in serous effusion specimens.
Shield PW; Papadimos DJ; Walsh MD
Cancer Cytopathol; 2014 Apr; 122(4):307-12. PubMed ID: 24421220
[TBL] [Abstract][Full Text] [Related]
11. CDX2, SATB2, GATA3, TTF1, and PAX8 Immunohistochemistry in Krukenberg Tumors.
Chiesa-Vottero A
Int J Gynecol Pathol; 2020 Mar; 39(2):170-177. PubMed ID: 32045390
[TBL] [Abstract][Full Text] [Related]
12. Young investigator challenge: The utility of GATA3 immunohistochemistry in the evaluation of metastatic breast carcinomas in malignant effusions.
Lew M; Pang JC; Jing X; Fields KL; Roh MH
Cancer Cytopathol; 2015 Oct; 123(10):576-81. PubMed ID: 26465236
[TBL] [Abstract][Full Text] [Related]
13. GATA3 expression in clinically useful groups of breast carcinoma: a comparison with GCDFP15 and mammaglobin for identifying paired primary and metastatic tumors.
Yang Y; Lu S; Zeng W; Xie S; Xiao S
Ann Diagn Pathol; 2017 Feb; 26():1-5. PubMed ID: 28038704
[TBL] [Abstract][Full Text] [Related]
14. GATA3 expression in breast carcinoma: utility in triple-negative, sarcomatoid, and metastatic carcinomas.
Cimino-Mathews A; Subhawong AP; Illei PB; Sharma R; Halushka MK; Vang R; Fetting JH; Park BH; Argani P
Hum Pathol; 2013 Jul; 44(7):1341-9. PubMed ID: 23375642
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic utility of the combined use of HNF4A and GATA3 in distinction between primary and metastatic breast and gastric carcinomas.
Saad DZ; Sidhom KF; Gadallah MF; Samir NA; Shakweer MM
APMIS; 2021 Sep; 129(9):548-555. PubMed ID: 34120367
[TBL] [Abstract][Full Text] [Related]
16. Serous carcinoma of the ovary and peritoneum with metastases to the breast and axillary lymph nodes: a potential pitfall.
Recine MA; Deavers MT; Middleton LP; Silva EG; Malpica A
Am J Surg Pathol; 2004 Dec; 28(12):1646-51. PubMed ID: 15577686
[TBL] [Abstract][Full Text] [Related]
17. GATA-3 and FOXA1 expression is useful to differentiate breast carcinoma from other carcinomas.
Davis DG; Siddiqui MT; Oprea-Ilies G; Stevens K; Osunkoya AO; Cohen C; Li XB
Hum Pathol; 2016 Jan; 47(1):26-31. PubMed ID: 26527523
[TBL] [Abstract][Full Text] [Related]
18. Napsin A and WT 1 are useful immunohistochemical markers for differentiating clear cell carcinoma ovary from high-grade serous carcinoma.
Rekhi B; Deodhar KK; Menon S; Maheshwari A; Bajpai J; Ghosh J; Shylasree ST; Gupta S
APMIS; 2018 Jan; 126(1):45-55. PubMed ID: 29266433
[TBL] [Abstract][Full Text] [Related]
19. The Novel Marker GATA3 is Significantly More Sensitive Than Traditional Markers Mammaglobin and GCDFP15 for Identifying Breast Cancer in Surgical and Cytology Specimens of Metastatic and Matched Primary Tumors.
Sangoi AR; Shrestha B; Yang G; Mego O; Beck AH
Appl Immunohistochem Mol Morphol; 2016 Apr; 24(4):229-37. PubMed ID: 25906123
[TBL] [Abstract][Full Text] [Related]
20. Napsin A is frequently expressed in clear cell carcinoma of the ovary and endometrium.
Iwamoto M; Nakatani Y; Fugo K; Kishimoto T; Kiyokawa T
Hum Pathol; 2015 Jul; 46(7):957-62. PubMed ID: 25971546
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
